Is Artiva Biotherapeutics, Inc. profitable?

Artiva Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $87.1M over the trailing twelve months, a -79.3% net margin.

What is Artiva Biotherapeutics, Inc.'s earnings per share?

Artiva Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.54.

Where does Artiva Biotherapeutics, Inc.'s income statement data come from?

Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Artiva Biotherapeutics, Inc. ARTV Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$71.8M+27.7%	$69.54M+38.2%	$65.86M+36.7%	$61.75M+29.4%	$56.23M+20.6%
General and administrative	$20.27M+8.2%	$20.27M+17.8%	$20.28M+31.5%	$19.83M+48.1%	$18.74M+37.8%
Other operating expenses	$92.07M+22.8%	$89.81M+33.0%	$86.15M+35.5%	$81.58M+33.5%	$74.96M+24.5%
Total operating expenses	$92.07M+22.8%	$89.81M+33.0%	$86.15M+35.5%	$81.58M+33.5%	$74.96M+24.5%
Operating income	-$92.07M-22.8%	-$89.81M-33.5%	-$86.15M-41.3%	-$81.58M-156%	-$74.96M-173%
Interest income	$5.01M-23.7%	$5.96M+11.4%	$6.97M+85.7%	$7.45M+220%	$6.56M+204%
Other income (expense), net	$5M+54.2%	$5.95M+211%	$6.96M+3,306%	$6.45M+1,154%	$3.24M+105%
Net income	-$87.07M-21.4%	-$83.87M-28.3%	-$79.19M-29.2%	-$75.13M-131%	-$71.72M-176%
Diluted earnings per share	-$3.54—	-$3.42—	——	——	——
Basic earnings per share	-$3.54—	-$3.42—	——	——	——
Weighted-average shares, diluted	98M+77.2%	97.6M+207%	84.5M+296%	78.9M+740%	55.3M+490%
Weighted-average shares, basic	98M+77.2%	97.6M+207%	84.5M+296%	78.9M+2,342%	55.3M+1,618%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$87.09M-21.1%	-$83.63M-27.1%	-$79.44M-29.8%	-$75.25M-131%	-$71.93M-179%
Net interest and investment income (loss)	$5.01M-23.7%	$5.96M+11.4%	$6.97M+85.7%	$7.45M+220%	$6.56M+204%
Unrealized gains (losses) on available-for-sale securities	-$18K+91.3%	$232K+153%	-$251K—	-$119K—	-$207K—
Other income, net (Note 6)	-$8K-162%	-$14K-109%	-$12K-104%	-$15K-104%	$13K-96.7%
Revenue from contracts outside the scope of ASC Topic 606	——	$0—	——	——	——
Change in fair value of interest rate swap	——	$0+100%	$0+100%	-$977K+67.1%	-$3.33M-317%
EBIT	-$92.07M-22.8%	-$89.81M-33.5%	-$86.15M-41.3%	-$81.58M-156%	-$74.96M-173%
EBITDA	-$89.43M-23.4%	-$87.21M-34.5%	-$83.6M-42.7%	-$79.07M-168%	-$72.49M—
EBITDA	-$89.43M-23.4%	-$87.21M-34.5%	-$83.6M-42.7%	-$79.07M-168%	-$72.49M—
EBIT	-$92.07M-22.8%	-$89.81M-33.5%	-$86.15M-41.3%	-$81.58M-156%	-$74.96M-173%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Artiva Biotherapeutics, Inc. profitable?: Artiva Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $87.1M over the trailing twelve months, a -79.3% net margin.
What is Artiva Biotherapeutics, Inc.'s earnings per share?: Artiva Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.54.
Where does Artiva Biotherapeutics, Inc.'s income statement data come from?: Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.